ProSomnus, Inc. (NASDAQ: OSA), a leader in the field of medical devices for the treatment of Obstructive Sleep Apnea (OSA), is proud to announce the publication of four abstracts in the esteemed Journal of Dental Sleep Medicine. This represents a major milestone in the progress of the company’s research and development efforts, and further cements their position as a frontrunner in the industry.
Join us for a showcase of the latest research and findings in the field of dental sleep medicine at the 2023 American Academy of Dental Sleep Medicine (AADSM) Annual Meeting! Taking place from May 19-21 in Philadelphia, Pennsylvania, attendees can look forward to engaging oral and poster presentations, as well as networking opportunities with leaders in the field. Don’t miss out on this opportunity to stay informed and ahead of the curve in dental sleep medicine!
Are you one of the millions of people suffering from Obstructive Sleep Apnea (OSA)? If so, ProSomnus has the perfect solution for you! ProSomnus is the first manufacturer of mass-customized Precision Oral Appliance Therapy (OAT) devices that are FDA-cleared and provide effective, economical, and patient-preferred treatment for OSA.
Unlike Continuous Positive Airway Pressure (CPAP) therapy, ProSomnus’s patented devices are a less invasive and more comfortable alternative. Research published by the Journal of Clinical Sleep Medicine and Military Medicine suggests ProSomnus’s Precision OAT devices are an effective treatment for mild to moderate OSA, while mitigating many of the side effects associated with alternative treatments.
With over 200,000 devices delivered and authorization by the Department of Defense and U.S. Army, ProSomnus’s devices are often covered by insurance, Medicare, and social health programs in key international markets. Take control of your health today – choose ProSomnus for your OSA treatment needs!